Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 23Withdrawn 3Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 19INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × ixazomib × Clear all
NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

NCT03733691 2023-10-25

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Oncotherapeutics

Phase 2 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡